Early decreases in TNFR-1 and TNFR-2 during canagliflozin treatment were independently associated with a lower risk of DKD progression, suggesting that TNFR-1 and TNFR-2 may also serve as potential pharmacodynamic markers of the response to SGLT2is. Here, TNFRSF1B is linked to diabetic kidney disease.